Why did you say that my marrow amplification abnormality was the first period of leukemia?

Mylodysplastic Syndromes, MDS, is a group of cloned blood diseases originating in blood stem cells, characterized by anomalous bone marrow blood function, a decrease in peripheral blood cells, and an increase in the risk of developing into acute myelical leukemia (Acute Myeloid Leukemia, AML). The following is a detailed explanation of why MDS was described as a pre-leukemia state:Characteristics of osteomosis.Cloning blood: The cloning mutations of blood stem cells in MDS patients have resulted in abnormal blood production functions. This cloned blood is a common feature of MDS and leukaemia.Declining blood cells: MDS patients usually show a decrease in one or more blood cells (red cells, white cells, slabs), similar to those with leukaemia.Marrow development abnormality: MDS patients have abnormality in their bone marrow development and maturity, which is the pathology of MDS.Basis of pre-leukemia stateGenetic and molecular changes: There are a number of genetic and molecular changes in MDS patients, which overlap with changes in acute myelitis leukaemia. For example, chromosome anomalies (e.g. + 8, 5/5q-, 7/7q- etc.) are common in MDS and AML.(a) Progress of diseases: MDS is considered to be a spectrum of diseases, ranging from mild bone marrow disorders to high-risk MDS, which may eventually progress to AML. According to statistics, about 30 per cent of MDS patients develop into AML in a few years.Risk classification: According to the MDS International Pre-Award Rating System (IPSS-R), patients are divided into different risk groups, with a significant increase in AML-related risks for those at high risk.Mechanism for MDS conversion to leukaemiaEvolution of cloning: The evolution of cloning of blood stem cells in MDS patients, which may accumulate more genetic and molecular anomalies over time, is a key step in the progress of the disease to AML.Marrow micro-environment change: MDS patients ‘ marrow micro-environment may contribute to the expansion of abnormal cloning and inhibit normal blood production, thus facilitating the growth of leukaemia cells.Immunological surveillance is lacking: normal immune systems can monitor and remove abnormal cells. In MDS, immunization surveillance may be compromised, allowing for the survival and proliferation of abnormal cloning.Clinical significanceMonitoring and prevention: MDS patients need to be closely monitored because of the risks of MDS progress being AML. Regular bone marrow examinations, blood routines and molecular genetic tests can help to detect early signs of disease progress.Treatment strategy: For high-risk MDS patients, a more aggressive treatment strategy may be needed to prevent or delay leukaemia. These treatments may include chemotherapy, immunosuppressants, blood growth factors support treatment and even stem cell transplants.ConclusionsAnomalous syndrome of bone marrow is known as the pre-prevalence of leukaemia because of its genetic and molecular characteristics, similar to leukaemia, and because of the risk of progress towards acute leukaemia. MDS ‘ cloned stem blood cells and an abnormal microcosm of bone marrow provide the basis for leukaemia. Therefore, early identification, risk assessment and appropriate treatment of MDS patients are essential to prevent leukaemia.